secwatch.observer — SEC 8-K summary
======================================

Issuer:     CONMED Corp (CNMD)
CIK:        0000816956
Form:       8-K
Filed at:   2025-12-05T23:59:59+00:00
Accession:  0001213900-25-118476
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CONMED to exit gastroenterology lines; terminates Gore VIABIL agreement effective Jan 1, 2026
--------------------------------------------------------------------------------

- Gastroenterology product lines expected to generate $90M–$95M revenue in 2025 with ~45% gross margins.
- Exit projected to cause EPS dilution of $0.45–$0.55 in 2026.
- Consolidated gross margin expected to improve by ~80 bps after exit completion.
- CONMED reaffirms full-year 2025 revenue guidance of $1.365B–$1.372B and adjusted EPS of $4.48–$4.53.
- 2026 guidance to be provided on Q4 2025 earnings call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/816956/000121390025118476/0001213900-25-118476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/816956/000121390025118476/ea0268554-8k_conmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-118476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer